Bace1 activity in cerebrospinal fluid and its relation to markers of ad pathology

Journal of Alzheimer's Disease

Volumn 20, Issue 1, 2010, Pages 253-260

  Mulder, Sandra D ^a,b   Van Der Flier, Wiesje M ^a,b   Verheijen, Jan H ^c   Mulder, Cees ^a,b   Scheltens, Philip ^a,b   Blankenstein, Marinus A ^a,b   Hack, C Erik ^a   Veerhuis, Robert ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TNO   (Netherlands)

Author keywords

Alzheimer's disease; A 40 A ; BACE1 activity; CSF biomarker profile; p tau; t tau; 42

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; TAU PROTEIN; THREONINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 77954553745     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1367     Document Type: Article

References (40)

1. Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H and Hampel H (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129, 3035-3041.
2. Strozyk D, Blennow K, White LR and Launer LJ (2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60, 652-656.
3. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H and Pirttila T (2009) Cerebrospinal fluid {beta}- amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66, 382-389.
4. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL and DeKosky ST (2008) Post-mortem correlates of in vivo PiBPET amyloid imaging in a typical case of Alzheimer's disease. Brain 131, 1630-1645.
5. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC and Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59, 512-519.
6. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Langstrom B and Nordberg A (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29, 1456-1465.
7. Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA,Windhorst AD, Scheltens P, Lammertsma AAand van Berckel BN(2009) Relationship of Cerebrospinal Fluid Markers to 11C-PiB and 18F-FDDNP Binding. J Nucl Med 50, 1464-1470.
8. Hardy JA and Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
9. Selkoe DJ (1991) The molecular pathology of Alzheimer's disease. Neuron 6, 487-498.
10. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M and Vassar R (2001) Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4, 231-232.
11. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawabe TT,Kola I, Kuehn R, Lee M, Liu W, Motter R, Nichols NF, Power M, Robertson DW, Schenk D, Schoor M, Shopp GM, Shuck ME, Sinha S, Svensson KA, Tatsuno G, Tintrup H, Wijsman J, Wright S and McConlogue L (2001) BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 10, 1317-1324.
12. Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, Verma IM and Masliah E (2005) Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 8, 1343-1349.
13. Fukumoto H, Cheung BS, Hyman BT and Irizarry MC (2002) Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59, 1381-1389.
14. Li R, Lindholm K,Yang LB,Yue X, Citron M,Yan R, Beach T, Sue L, Sabbagh M, Cai H,Wong P, Price D and Shen Y (2004) Amyloid beta peptide load is correlated with increased betasecretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci USA 101, 3632-3637.
15. Stockley JH, Ravid R and O'neill C (2006) Altered betasecretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer's disease brain. FEBS Lett 580, 6550-6560.
16. Tyler SJ, Dawbarn D,Wilcock GK and Allen SJ (2002) alphaand beta-secretase: profound changes in Alzheimer's disease. Biochem Biophys Res Commun 299, 373-376.
17. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L, Simon AJ and Blennow K (2008) Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 65, 1102-1107.
18. Geslani DM, Tierney MC, Herrmann N and Szalai JP (2005) Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer's disease. Dement Geriatr Cogn Disord 19, 383-389.
19. Visser PJ, Kester A, Jolles J and Verhey F (2006) Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 67, 1201-1207.
20. Zhong Z, Ewers M, Teipel S, Burger K,Wallin A, Blennow K, He P, McAllister C, Hampel H and Shen Y (2007) Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 64, 718-726.
21. McKhann G, Drachman D, Folstein M, Katzman R, Price D and Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
22. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG and Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56, 303-308. (Pubitemid 29120227)
23. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ and Cras P (1993) Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 61, 1828-1834.
24. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K andVanmechelen E (2000) Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7, 245-258.
25. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N and Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285, 49-52.
26. Schoonenboom SN, Visser PJ, Mulder C, Lindeboom J, van Elk EJ, van Kamp GJ and Scheltens PH (2005) Biomarker profiles and their relation to clinical variables in mild cognitive impairment. Neurocase 11, 8-13.
27. Schuitemaker A, Dik MG, Veerhuis R, Scheltens P, Schoonenboom NS, Hack CE, Blankenstein MA and Jonker C (2009) Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging 30, 1885-1889.
28. Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, van Elk EJ, van Kamp GJ, van Swieten JC and Scheltens P (2004) Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 62, 1580-1584.
29. Verheijen JH, Huisman LG, van Lent N, Neumann U, Paganetti P, Hack CE, Bouwman F, Lindeman J, Bollen EL and Hanemaaijer R (2006) Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin Chem 52, 1168-1174.
30. Blennow K and Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2, 605-613.
31. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de LM, Hampel H, Scheltens P, Pirttila T,Wallin A, Jonhagen ME, Minthon L, Winblad B and Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
32. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K and Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5, 228-234.
33. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM and Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
34. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L and Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 8, 619-627.
35. Borghi R, Patriarca S, Traverso N, Piccini A, Storace D, Garuti A, Gabriella C, Patrizio O and Massimo T (2007) The increased activity of BACE1 correlates with oxidative stress in Alzheimer's disease. Neurobiol Aging 28, 1009-1014.
36. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y and Kawashima S (1995) Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 14, 457-466.
37. Cho HJ, Kim SK, Jin SM, Hwang EM, Kim YS, Huh K and Mook-Jung I (2007) IFN-gamma-induced BACE1 expression is mediated by activation of JAK2 and ERK1/2 signaling pathways and direct binding of STAT1 to BACE1 promoter in astrocytes. Glia 55, 253-262.
38. Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE and Ikezu T (2007) Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 170, 680-692.
39. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T and van Leuven F (2005) Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP [V717I] transgenic mice. J Neuroinflammation 2, 22.
40. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, Muraca G, Danni O, Zhu X, Smith MA, Perry G, Jo DG, Mattson MP and Tabaton M (2008) Oxidative stress activates a positive feedback between the gamma- and betasecretase cleavages of the beta-amyloid precursor protein. J Neurochem 104, 683-695.